Rucaparib for treating high cholesterol from lorlatinib
Treatments studied
Part of Cancer, Hormones & metabolism clinical trials.
This trial tests a monoclonal antibody (rucaparib) to treat high cholesterol caused by the lung cancer drug lorlatinib. It is for people with advanced ALK-positive non-small cell lung cancer who have developed high cholesterol from lorlatinib treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old.
- You have advanced (stage IIIB, IIIC, or IV) ALK-positive non-small cell lung cancer.
- High cholesterol (Grade 1 to 3) developed after taking lorlatinib.
- Your fasting triglyceride level is below 5.6 mmol/L.
- No known inherited high cholesterol disorder (familial hypercholesterolemia).
- No other cholesterol-lowering antibody therapy in the last 6 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests adding cholesterol-lowering drugs to manage high cholesterol caused by lorlatinib, a targeted therapy for advanced ALK-positive non-small cell lung cancer. It aims to help patients stay on lorlatinib safely while controlling their cholesterol levels.
This study looks at how the drug Lorlatinib affects cholesterol levels in people with ALK-positive non-small cell lung cancer. It aims to understand and manage these side effects better.
This study is testing a targeted therapy called lorlatinib in people with advanced ALK-positive lung cancer. It aims to see how well this oral medication works in a real-world setting.
This trial tests a combination of two drugs for people with a specific type of advanced lung cancer that has a change in the ALK gene. The goal is to see if this combination works better than current treatments and to use a blood test to guide therapy.
This trial tests a targeted pill, lorlatinib, for people with advanced ALK-positive non-small cell lung cancer (NSCLC) who have not received previous treatment for advanced disease. It aims to see how well the drug works in this setting.
This trial tests combining chemotherapy with lorlatinib for people with ALK-positive lung cancer that has spread outside the brain while on lorlatinib. The goal is to see if adding chemo can help control the cancer when it starts growing again.
Hear when a new ALK Fusion-positive Non-small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.